A myotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurodegenerative disease that selectively kills brain and spinal cord motor neurons (reviewed in ref. 1) . Although most ALS cases are sporadic and of unknown origin, some familial instances are caused by acquired toxic properties of dominant missense point mutations in the ubiquitously expressed superoxide dismutase 1 (SOD1) independent of its dismutase activity (2, 3) . Because both familial and sporadic forms lead to what is nearly indistinguishable diseases, the analysis of mutant (human or mouse) SOD1-overexpressing rodent ALS models, which develop a fatal, late-onset, progressive ALS-like paralysis (4-7), can provide valuable tools for dissecting the overall ALS disease mechanism.
The central question in understanding ALS in mutant SOD1-expressing mouse and rat models is what are the slowly acting toxic mechanisms, or build-up of toxic products that are responsible for ultimately leading to the degeneration of the most at-risk cell type, the large spinal cord motor neurons (1) . Such properties of mutant SOD1 seem likely to induce responses in the genes expressed by motor neurons (their transcriptome) at early disease stages or even before obvious clinical symptoms. Identifying the manner in which motor neurons respond to, or are affected by, ALS-linked mutant SOD1-induced damage could provide key insights either into primary mechanisms of toxicity or to potential therapeutic approaches that may be successful in slowing disease progression in ALS.
High-density oligonucleotide microarrays provide an excellent tool to test on a genome wide level the effects of candidate events on the cellular expression profile. Because certain aspects of ALS are non-cell autonomous and originate from mutant SOD1 accumulation in non-motor neuronal cells (8, 9) , cell-type specificity is of high importance when using such an approach. To date, three main gene-expression profiling studies have been reported (10) (11) (12) , all of which were restricted to analysis of the adult disease phase in one SOD1 mouse line that accumulates a dismutase active mutant to extraordinarily high levels during disease progression [between 10-and 20-fold over the already abundant endogenous mouse SOD1 (4, 13) ]. Two studies (10, 11) used the entire spinal cord, thus losing cell-type specificity and masking mRNA changes within motor neurons as a consequence of the much more numerous glial cells and their activation before or during disease progression. A more recent effort (12) used profiling by laser microdissection of motor neurons. The major outcome of this study was an elevation of vimentin beginning in the presymptomatic phase. No comparison was undertaken to evaluate changes due simply to accumulation of high levels of SOD1 protein and activity (e.g., by parallel analysis of similar motor neurons from mice expressing high levels of human wild-type SOD1). In any case, no insights on dysregulated candidates common to SOD1 mutants of divergent biochemical characters can be identified from these earlier efforts.
Using both purified embryonic and adult motor neurons collected by laser microdissection, in combination with Affymetrix GeneChips, (Affymetrix, Inc., Santa Clara, CA) gene dysregulations that arise within the at-risk motor neurons before the overall appearance of clinical symptoms are now identified by the following: (i) analysis of expression profiles from embryonic motor neurons of rats expressing high levels of mutant SOD1 G93A as compared with wild-type overexpressing SOD1 controls that do not develop disease; and (ii) analysis of expression profiles at adult stages before appearance of overall clinical symptoms within motor neurons isolated from mice expressing dismutase active (SOD1 G37R ) or inactive (SOD1 G85R ) SOD1 mutants, as compared with motor neurons isolated from mice expressing high levels of wild-type SOD1 or normal motor neurons. Two molecular pathways are identified whose dysregulation is common to dismutase active and inactive mutants. present in vivo, whole transcriptome gene expression profiling (Affymetrix Rat 230v2.0 GeneChip; 30,000 transcripts) was performed on highly pure spinal cord motor neurons from embryonic day (E) 14 rats expressing similar levels of either mutant (SOD1 G93A ) or wild-type (SOD1 WT ) human SOD1 ( Fig.  1 and Tables 1 and 2 ). Independent preparations of motor neurons from four mutant SOD1
G93A and three wild-type SOD1
WT preparations (see Materials and Methods) were directly isolated without any in vitro culturing and then compared.
Surprisingly few significant mRNA changes (using high stringency: minimal lowest fold change Ն1.50) were present despite Ϸ50% of the 30,000 tested transcripts expressed above background levels. Only 12 genes were dysregulated (Table 2) . Among them, transcripts up-regulated in mutant SOD1 motor neurons were Cxcr3 (a chemokine receptor), Adamts16 (metallopeptidase) and Rbm8 (RNA binding protein; mRNA processing). Transcripts down-regulated in mutant SOD1 motor neurons were Ndufc2 (mitochondrial NADH dehydrogenase component), Rnmt (mRNA CAP complex; mRNA processing), and Sc5d (sterol-desaturase; fatty-acid metabolism). The chemokine receptor Cxcr3 would be expected to be expressed on microglial rather than neuronal cells (14) . However, the high purity of the isolated motor neurons and the absence of several markers for potential microglial contaminants (including CD11b and Iba1) ( Table 1 ) strongly suggested this Cxcr3 induction to reflect a surprising mutant-dependent neuronal mRNA change.
Previous studies had suggested that after culturing in vitro early embryonic motor neurons from ALS model mice were already adversely affected by mutant SOD1 expression. Such changes included altered excitability and altered AMPA receptor responses and an increased sensitivity of the Fas cell-death pathway to exogenous activation (15) (16) (17) (18) . None of these correlated with mutant SOD1-induced transcriptional alterations in embryonic motor neurons in vivo. There were no mutantdependent gene dysregulations among the components of the Fas cell-death pathway (including FasL, Fas, Fadd Daxx, p38, nNOS, and Casp8) ( Table 2 ), demonstrating that mutantdependent increased sensitivity of this network (18) is not based on mRNA dysregulations or requires additional aging/stressing to be revealed.
Major, Age-Dependent Gene Dysregulations in Adult Motor Neurons
Long Before Appearance of Clinical Symptoms. To find gene dysregulations in adult motor neurons of mutant SOD1-expressing mice before the appearance of overall clinical symptoms, we focused initially on the group of dismutase active SOD1s. We used laser microdissection to isolate motor neurons from mice expressing comparable levels of either mutant SOD1 G37R or wild-type SOD1 WT (Fig. 2) . Two presymptomatic time points were chosen (8 weeks and 15 weeks of age), both long before the appearance of overt clinical symptoms (hind limb weakness appears at Ϸ22 weeks and paralysis at Ϸ25 weeks) (Fig. 2 A) . Animal weight has been demonstrated (19) to be a simple, reliable measure for disease ''onset'' and progression in these mice, with continuing weight gain in the presymptomatic phase (up to 15 weeks) and denervation-induced weight loss in the symptomatic phase (starting at 22 weeks) (Fig. 2B) . The inflection point of the weight curve provides a simple definition of Mutant SOD1-induced gene dysregulations (average fold changes) comparing (noncultured, freshly isolated) purified preparations of mutant SOD1 G93A (n ϭ 4) and wild-type SOD1 WT (n ϭ 3) expressing embryonic motor neurons. ) and wild-type (SOD1 WT ) human SOD1 (hSOD1) rats (rSOD1; endogenous rat SOD1). (B and C) Purified embryonic (E14) motor neurons were cultured for 7 days in vitro and stained for choline acetyltransferase (ChAT) to test the viability and purity of the isolated motor neurons. Gene expression profiling was performed on noncultured, freshly isolated embryonic (E14) motor neurons from mutant SOD1 G93A and wild-type SOD1 wt rats (see Tables 1 and 2 disease onset, although it is before obvious symptoms (normal hind limb spread reflex, fully active moving behavior) and with normal number and bimodal caliber distribution of lumbar L5 motor axons ( Fig. 2 A, C, and D). Denervation has already initiated at this point (seen, for example, in the gastrocnemius hind limb muscle; Fig. 2E ). Continued denervation induced muscle atrophy is reflected in the symptomatic phase by near complete loss of neuromuscular junctions, axonal degeneration, weight loss, hind limb weakness and paralysis ( Fig. 2 D and E) .
From each spinal cord, laser microdissection was used to isolate Ϸ3,000 motor neurons from the lumbar L4-L6 region, the area most affected in ALS mice (Fig. 3) . Two-round linear amplification of total RNA was hybridized to Affymetrix GeneChips (Mouse MOE430A/B GeneChip-Set; 39,000 transcripts). RT-PCR of the isolated RNA revealed an Ϸ50-fold enrichment of motor neuron mRNAs versus whole spinal cord (Fig. 3G ). Because measurement (Bioquant Software) determined that motor neurons in a lumbar spinal cord cross section occupy Ϸ2% of the total area, this ratio established that essentially all of the RNA was derived from motor neurons.
For the 8-and 15-week time points, both of which are before the appearance of overall symptoms at 22 weeks, we used biological replicate samples of three or four mice per mutant SOD1 G37R and three mice per wild-type SOD1
WT line (one mouse per MOE430A/B GeneChip-Set; only females were used). Analysis of the motor neuron expression profiles was performed with GCOS v1.2 (Affymetrix) in combination with dChip v1.3 (20) . All samples showed an average of Ϸ50% of all of the 39,000 transcripts to be present (above background level). At the very early presymptomatic 8-week time point, only seven genes were dysregulated (using high stringency: minimal lowest fold change Ն1.50); transcripts up-regulated in mutant SOD1 motor neurons were: Phgdh (D/L-serine-biosynthesis) and Hspa1a (heat-shock protein 1A); whereas transcripts downregulated in mutant SOD1 motor neurons were: Tnfrsf1b (TNF receptor 2), Hbb (hemoglobin beta-chain), Tmem10 (membrane protein), Dbp (transcription factor; involved in detoxification) and an expressed sequence tag (EST) (EST 1445268at) [ Table  3 and supporting information (SI) Tables 4 and 5] .
However, during the presymptomatic phase between 8 and 15 weeks, a major motor neuron response resulted in the dysregulation by Ն1.50-fold of Ϸ108 genes by the 15-week onset time point (using high stringency; minimal lowest fold change Ն1.50). Eighty one genes were up-regulated and 27 genes were downregulated in mutant SOD1 motor neurons (Table 3 and SI Tables  4 and 5) . Of these 108 genes, the most promising candidates could be grouped in the following eight functional groups: D/L-serine-biosynthesis (Phgdh, Phsph, Psat), neuronal regenerative/injury response (Sprr1a, CD44, ATF3, Adcyap1, Fos, Fn14, GAP-43, Gadd45a, Marcks), unfolded protein-response/ERstress (ATF4, Ddit3/CHOP10), neuronal cell-cycle reentry (Ccnd1), lysosomal degradation machinery (Ctss, Laptm5, Hexb), apoptosis-related (Noxa, Nupr1, Clic4, Ldoc1), mitochondrion-associated (Pck2, Noxa, Clic4) and the complement system (C1qa, C1qb, C1qc, Daf1). All of these genes were up-regulated in mutant SOD1 motor neurons, except two (Ldoc1 and Daf1) ( Table 3 and SI Tables 4 and 5) .
Comparing these two (symptom-free) time points revealed that two of the 7 genes dysregulated already at 8 weeks were increasingly (and in the same direction) also dysregulated at 15 weeks: Phgdh (D/L-serine-biosynthesis) was up-regulated (2.9-to 5.2-fold) and a gene previously identified only as an EST (EST-1445268at) was down-regulated (1.9-to 3.2-fold). Seven of the 108 that were dysregulated at 15 weeks (fold changes between 1.8 and 5.2) were already dysregulated in the same direction, but less strongly at 8 weeks (using low stringency; minimal average fold change Ն1.5). These genes included Psph (D/L-serine-biosynthesis), Ddit3/CHOP10 (unfolded protein response/ER-stress), Pck2 (mitochondrial, gluconeogenesis), Ldoc1 (apoptosis-related), Ifrd1 (transcriptional repressor), Ddr2 and Chac1 (all up-regulated, except Ldoc1) ( Table 3 and  SI Tables 4 and 5) . None of these genes dysregulated in the SOD1 G37R mice were overlapping with dysregulated genes found in mutant SOD1-expressing E14 embryonic motor neurons (Table 2 and SI Tables 4 and 5) . (21) . By 8 weeks both Phgdh (3-Phosphoglycerate dehydrogenase) and Psph (Phosphoserine phosphatase) were induced (by 2.9-and 1.7-fold, respectively) in mutant SOD1 motor neurons. By 15 weeks, induction of both (Phgdh and Psph) increased and Psat1, the third of the three major enzymes known to be involved in the synthesis of D/L-serine, was also up-regulated (1.9-fold; Table 3 and SI Tables 4 and 5 ). Immunohistochemistry was used to confirm the mRNA induction at a protein level. Phgdh, although known to be constitutively expressed in glial cells (21) , was clearly induced in a subset of large lumbar ventral horn motor neurons in 15-week-old (onset) mutant SOD1 G37R mice, but was completely absent in motor neurons of age-matched wild-type SOD1 WT control mice (Fig. 4) .
In addition to Phgdh, Noxa (phorbol-12-myristate-13-acetateinduced protein 1, Pmaip1; apoptosis-related) and CD44 (CD44 antigen; neuronal regenerative/injury response; ref. 22) , two other candidates which showed strong mRNA induction at 15 weeks (onset) (5-fold and 14-fold, respectively) were chosen for confirmation at the protein level. Noxa was specifically found within large ventral horn motor neurons, albeit no difference in the level of protein accumulation could be detected between mutant and wild-type SOD1
WT mice either at onset or symptomatic stages (SI Fig. 7 and data not shown) . However, immunohistochemistry clearly confirmed the up-regulation of CD44 within a subpopulation of large ventral horn lumbar motor neurons in 15-week-old (onset) mutant SOD1 G37R mice whereas Table 3 . Gene dysregulations appearing before the appearance of overt symptoms and induced by dismutase active and inactive SOD1 mutants within motor neurons of SOD1 G37R and SOD1 G85R mice Shown are the 29 most promising candidate genes that were dysregulated in mutant SOD1 G37R mice by the 15-week ''onset'' time point (average fold-changes indicated for onset; for the full list, see SI Tables 4 and 5 ). Candidates that were also dysregulated in motor neurons of SOD1 G85R mutants are indicated in the fourth column and marked in red (for the full list, see SI Tables 4 -6 ). The D͞L-serine biosynthesis pathway (highlighted with a dotted box) was early-on induced in dismutase-active SOD1 G37R mutants, whereas candidate genes of the neuronal regenerative͞injury response and the classic complement pathway (highlighted with solid boxes) were induced in both SOD1 G37R and SOD1 G85R mice.
it was absent from age-matched wild-type SOD1
WT motor neurons (SI Fig. 7) .
Dysregulation of the Complement Cascade Within Motor Neurons.
A very unexpected finding was that components of the classic pathway of the complement cascade were expressed and dysregulated in mutant SOD1 motor neurons. By disease onset (15 weeks), mRNAs for all of the three subunits of the C1q protein [C1qa, C1qb, C1qc (complement component 1; q subcomponent; ␣, ␤, and ␥ polypeptides)] were strongly induced in mutant SOD1-expressing motor neurons (Table 3 and SI Tables 4 and  5 ). C1q, a secreted, extracellular polypeptide which can bind antibody aggregates, is the main initiating factor for the classic complement pathway (23) . Although in the central nervous system complement components would be expected to be produced by the resident immune cells rather than by motor neurons, markers like CD11b and Iba1 (both measures for potential microglial contaminants) were not detectable by GeneChip analysis (''Absent'') in the mRNA pool of laser microdissected motor neurons. In addition, one of the major cellular complement cascade inhibitors, Daf1 (decay-accelerating factor 1; CD55; GPI-attached extracellular membrane protein), was down-regulated at this same onset time point, further demonstrating mutant SOD1-induced dysregulation of neuronally derived complement components.
Gene Dysregulations Common to Dismutase Active and Inactive Mutants.
To assess the significance of the identified gene dysregulations in motor neurons of mutant SOD1 G37R mice as candidate transcriptional changes involved in a common mechanism of toxicity arising from SOD1 mutants of divergent biochemical character, we expanded our gene expression profiling to motor neurons from mice that develop ALS-like motor neuron disease from expression of the dismutase inactive mutant SOD1 G85R , which causes disease in mice when accumulated to levels below that of endogenous mouse SOD1 (levels 5-to 50-fold below that needed for disease from dismutase active mutants) (5) .
One well studied mutant SOD1 G85R mouse line (5, 24) reaches end stage at Ϸ12-13 months of age, a time significantly later than the SOD1 G37R mice (Ϸ25 weeks). The later disease onset in this line produces more variable timing of disease stages than is seen in the SOD1 G37R mice, with the inflection point of the weight curve (onset) between 7.5 and 9 months, whereas overall clinical symptoms (including hind limb weakness) appear at Ϸ11-12 months and end stage (defined by hind limb paralysis) is reached at Ϸ12-13 months. Overall behavior of the SOD1 G85R mice (hind limb spread reflex, overall activity) and the integrity of the motor neuron unit (axon number, axon caliber distribution, muscle innervation) were very similar to the corresponding onset time point (15 weeks) in SOD1 G37R mice ( Fig. 2 and SI Fig. 8 ). Because in SOD1 G37R mice dysregulation of 108 genes appeared at onset, we chose this time point for laser microdissection recovery of motor neurons from SOD1 G85R mice, followed by gene expression profiling. Because SOD1 G85R accumulates to less than endogenous mSOD1 (Fig. 2) , nontransgenic littermates were chosen as the most appropriate comparison animals. To compensate for the spread of the onset in SOD1 G85R mice, two time points, 7.5 and 9 months, were analyzed and candidates with an average fold change Ն1.5 (low stringency) in either of them were selected (Table 3 and SI Tables 4 and 5 ; for high stringency data see SI Table 6 ). For each time point, four mutant and three control mice were used (as for the SOD1 G37R line, only females were taken).
A common set of 21 genes was found to be dysregulated in motor neurons of both the SOD1 G37R and the SOD1 G85R mice by disease onset (Table 3 and SI Tables 4-6 ). The most promising candidates fell into three groups: neuronal regenerative/injury response (ATF3, CD44, Fos, Sprr1a), the classic complement system (C1qa, C1qb, C1qc) and lysosomal degradation machinery (Laptm5, Hexb [HEXB-mutations are linked to the neurodegenerative Sandhoff-disease (25)]). Additional genes dysregulated in common between dismutase active and inactive mutants included Serpinb1a (a serine protease inhibitor), Aqp4 (a water-channel), Grn [granulin; growth-factor related; GRN-mutations are linked to frontotemporaldementia (FTD-17) (26)] and Gtl2 (untranslated regulatory RNA) (all of the transcripts were up-regulated in mutant SOD1 motor neurons, except Gtl2, which was downregulated).
Immunohistochemistry with available antibodies was used to confirm that the mRNA dysregulations were ref lected in changes in accumulated proteins within motor neurons. At onset (at 15 weeks in SOD1 G37R and at 9 months in SOD1 G85R mice), both Sprr1a and ATF3 were clearly selectively induced in a subset of large lumbar ventral horn motor neurons. Parallel analysis of spinal cords from age-matched mice expressing high levels of wild-type human SOD1 or nontransgenic mice showed no detectable staining in any cell-type (Fig. 5) . Induction of Sprr1a and ATF3 was further increased in the symptomatic phase (at Ϸ22 weeks in SOD1 G37R and at Ϸ11-12 months in SOD1 G85R mice), although still only in a subset of motor neurons (Fig. 5) .
Glial activation in the vicinity of the affected neurons was found only after onset, indicating that the induction/dysregulation of Sprr1a and ATF3 is an early event in the motor neuron response to mutant SOD1 toxicity (Fig. 5) . A subset of lumbar ventral horn motor neurons of both SOD1 G37R and SOD1 G85R mice also showed immunoreactivity for complement (C1q) (Fig. 6) , whereas age-matched control animals did not, confirming the induction of complement in motor neurons.
Discussion
Cell-type specific gene expression profiling of the at-risk spinal cord motor neurons in mutant SOD1-expressing ALS rodent models has revealed three important findings.
First, there are no inherent mutant SOD1-induced mRNA changes at the developmental birth of embryonic motor neurons. Although embryonic motor neurons have been argued to be already adversely affected by mutant SOD1 expression (15) (16) (17) (18) , it is now clear that these effects are not the result of mutant SOD1-induced transcriptional changes in vivo. Rather, because deficits in embryonic motor neurons are seen only after culture in vitro, this additional stress is required to induce/reveal mutantdependent changes.
Second, mutant SOD1 toxicity establishes its effects on mRNA dysregulations in an age-dependent manner and marked transcriptional changes arise in adult motor neurons well before the appearance of overt clinical symptoms. Indeed, major mutant SOD1-induced gene dysregulations develop during the presymptomatic postnatal adult lifespan of the at-risk motor neurons, underlining the need for an age-dependency for the overall toxic process (8, 9) .
Third, a common set of gene dysregulations originate from dismutase active and inactive mutants. Indeed, a set of 21 genes were dysregulated in dismutase active and inactive mutants before the appearance of the overall symptomatic phase, three of which (Sprr1a, ATF3, C1q) we confirmed at a protein level. Thus, motor neuron specific induction/dysregulation of these proteins is common to SOD1 mutants of divergent biochemical characters.
The significance of these findings is amplified by our analysis of the data from an earlier gene array study (12) with an additional dismutase active SOD1 mutant (SOD1 G93A ). The analysis revealed a 43% overlap (49 genes) with our own dismutase active mutant SOD1 G37R data set, including all our major functional candidate groups (SI Tables 4 and 5 ). None of these 49 genes, with the exception of vimentin, were initially recognized as promising candidates, perhaps because of masking from the use of nontransgenic littermates as the comparison animals instead of the more appropriate wild-type SOD1 transgenic mice.
Most importantly, inspection of genes dysregulated within motor neurons in all three mutant lines of SOD1 mice produced a set of 16 dysregulated genes common to all of the mutant lines, including our two most promising functional groups of neuronal regenerative/injury response (ATF3, Sprr1a, CD44) and neuronally derived components of the classic complement pathway (all three subunits of C1q) (SI Tables 4 and 5 ). Candidates of the neuronal regenerative/injury response (Sprr1a/ATF3/CD44) are known to be strongly induced by axonal injury in affected neurons (22, 27, 28) (SI Tables 4 and 5 ) and ATF3 (together with another of our candidates Ddit3/CHOP10) have been shown, on a protein level, to be induced in SOD1 G93A mice (29) . In light of a report of mutant SOD1 G93A -dependent impairment of the axonal regenerative response (30) , the simplest view is that induction of this pathway is a compensatory response.
The unexpected induction of mRNAs of the classic complement pathway (C1qa, C1qb, C1qc) long before appearance of obvious clinical symptoms and before major neuroinflammation suggests that mutant SOD1-induced up-regulation of motor neuron derived complement components is a likely aspect of a toxicity developed within motor neurons that contributes to neurodegeneration. C1q is a secreted, extracellular polypeptide which can bind antibody aggregates and is the main initiating factor for the classic complement pathway which is used to clear/lyse (antibody-marked) debris, pathogens and injured or degenerating cells (23) . Complement activation has been associated with several neurodegenerative diseases, including ALS, Parkinson's and Alzheimer's (31) (32) (33) (34) (35) and analysis of entire spinal cords from mutant SOD1 G93A mice showed transcriptional up-regulation of complement components at early symptomatic stages (10) . C1q components have also previously been suggested to be produced by injured or stressed neurons, especially in Alzheimer's disease (36) (37) (38) (39) (40) . Furthermore, deletion of C1q has been shown to reduce pathological signs in APP-transgenic Alzheimer-mice (41) . In light of the recent finding that a proportion of mutant SOD1 may be secreted (42) , as well as liberated by cell death, and therefore could act from outside the motor neurons, it is tempting to speculate that the induced complement system might recognize such extracellular, misfolded mutant SOD1 and mark the motor neuron for attack by immune cells.
Thirty-three genes were also identified to be specifically induced/ dysregulated by a pair of dismutase active mutant SOD1s (SOD1 G37R , this study; SOD1 G93A (12) ; SI Tables 4 and 5 ). Among the most provocative candidate pathways was the early dysregulation of the D/L-serine biosynthetic pathway (SI Tables 4 and 5 Future studies are needed to assess whether modulating the neuronal regenerative/injury candidate genes found in our study (Sprr1a/ATF3/CD44) can increase the neuronal regenerative response and slow disease in ALS, whether systemic activation of the complement system in ALS and also the herein suggested role of neuron-specific induction of components of the complement pathway is detrimental or beneficial, and whether induction of the D/L-serine pathway is protective to stressed neurons.
Materials and Methods
Animals. Transgenic human SOD1-expressing mice, wild-type SOD1 WT , line 76 (6), mutant SOD1 G37R , line 42 (6) and mutant SOD1 G85R , line 148 (5), were on a pure C57BL/6 genetic background, whereas transgenic human SOD1-expressing rats, wildtype SOD1 WT (45) and mutant SOD1 G93A (7), were on a SpragueDawley genetic background. Genotyping was performed as described (46) . Embryonic Rat Motor Neurons. Embryonic motor neurons were purified from 14 day old (E14) heterozygous wild-type SOD1 WT or mutant SOD1 G93A rat embryos as described (47) by using a 6% Optiprep (Sigma, St. Louis, MO) gradient separation followed by immunopanning using an anti-p75 (low-affinity NGF receptor) antibody (Chemicon, Temecula, CA). Of each motor neuron preparation (five to seven hSOD1 WT or hSOD1 G93A positive embryos) an average of Ϸ100,000 highly pure large motor neurons were obtained. Cells were frozen at Ϫ80°C and Ϸ750 ng of total RNA could be extracted (Absolutely RNAMicroPrep Kit; Stratagene, La Jolla, CA; with DNase treatment). On the same day, both one mutant and one wild-type SOD1 motor neuron preparation were prepared. This step was repeated four times to give biological replicates. Additional procedures are described in SI Materials and Methods.
Laser Microdissection of Adult Mouse Motor Neurons. For both mutant SOD1 G37R and SOD1 G85R and wild-type SOD1 WT (or nontransgenic control) mouse lines, three to four animals were used per time point (females only). Lumbar spinal cords were rapidly recovered, rinsed and frozen in Ϫ40°C Isopentane in HistoPrep OCT compound (Fisher Scientific International, Hampton, NH), cryosectioned (20 m) and sections mounted on RNase-free PENfoil covered glass slides (Leica, Bannockburn, IL). Sections were fixed for 60 s in 75% EtOH, stained for 30 s in 4% cresyl-violetacetate/0.3% acetic-acid (Sigma) to identify motor neurons, dehydrated in graded solutions of ethanol (70%, 95%, 100%) followed by 45 s in xyelene and dehydrated for 1 h before laser microdissection (Leica AS/LMD-20). From one spinal cord Ϸ3,000 large ventral horn motor neurons (diameter Ն25 m) of the lumbar L4-L6 region were directly collected in lysis buffer and the lysate stored at Ϫ80°C. Approximately 150 ng of total RNA was recovered per 3,000 laser microdissected motor neurons [Absolutely RNANanoPrep Kit, Stratagene; with DNase treatment; quantified with a 20-l SubMicro Quartz Spectrophotometer Cell (Starna Cells, Atascadero, CA)] and RNA integrity was assessed on a Bioanalyzer 2100 (Agilent, Santa Clara, CA).
RNA Amplification and GeneChip Hybridization. For both laser microdissected and embryonic motor neurons, 100 ng of total RNA was used for two-round linear amplification (Eukaryotic Small Sample Target Labeling Assay Version II; Affymetrix, Santa Clara, CA) and per sample one Affymetrix Mouse MOE 430 A/B or Rat 230v2.0 GeneChip was hybridized with 15 g of biotinylated cRNA. All GeneChip hybridizations were performed either at the VA GeneChip Core Facility (University of California at San Diego) or the TGen Microarray Core Facility (Phoenix, AZ) as part of the National Institutes of Health Neuroscience Microarray Consortium according to standard Affymetrix protocols.
GeneChip Data Analysis. CEL files obtained by using GCOS v1.2 (Affymetrix) were analyzed with dChip v1.3 (20) , whereas ''Present/Absent'' calls were calculated with GCOS. In dChip, all mutant and control CEL files per time point were normalized and ''model-based expression-indexes'' were calculated by using the match/mismatch model (20) . Comparison analysis between three to four mutant and three control samples was performed with dChip by using genes that were called ''Present'' on at least 50% of the chips in either the control or the mutant group per time point. Selection criteria were a minimal lowest fold change of Ն1.50 (high stringency) or a minimal average fold change of Ն1.5 (low stringency). For all gene names, NetAffx Annotation Update R21 (Nov 28, 2006) was used (Affymetrix). GeneChip raw data (CEL-files) were deposited at http://arrayconsortium. tgen.org (lobsi-affy-mouse-193446 and lobsi-affy-rat-194438) and will be available through the Gene Expression Omnibus (GEO) Database, www.ncbi.nlm.nih.gov/geo.
Immunohistochemistry, assessment of the integrity of the motor neuron unit, RT-PCR, immunoblotting, and additional details are described in SI Materials and Methods.
